Clinical Expression of Familial Hypercholesterolemia in Patients from France and French Canada Carrying Identical-by-Descent Pathogenic LDLR Gene Variants: A Proof-of-Concept Study
Open Access
- 26 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (19) , 5725
Abstract
Background: Studying patients carrying identical-by-descent (IBD) pathogenic gene variants allows us to control for the disease-causing genetic background and to more accurately document the impact of modifiers. Familial hypercholesterolemia (FH) is characterized by elevated low-density lipoprotein cholesterol (LDL-c) levels and premature atherosclerosis and is often caused by defects in the LDLR gene. There is a high prevalence of FH in French Canada as a result of a founder effect from France in the 17th century. Several FH patients currently living in French Canada (founder population) and in France (colonizing population) carry IBD FH-causing variants. The expression of FH is affected by environmental and genetic modifiers, and patients with IBD variants may present different characteristics. Methods: In this study, we compared FH clinical expression patients carrying IBD LDLR pathogenic variants living in France or Canada. Four IBD variants, namely c.259T>G p.(Trp87Gly), c.2000G>A p.(Cys667Tyr), c.682G>A p.(Glu228Lys), and c.1048C>T p.(Arg350*), were selected. Untreated plasma lipid profiles, the apolipoprotein E (APOE) genotype, cardiovascular risk factors, and the occurrence of symptomatic ASCVD were compared in 105 adult carriers (30 from France and 75 from French Canada). Results: All parameters were similar between the two populations, except for untreated total cholesterol (10.14 ± 1.89 mmol/L vs. 8.65 ± 1.84 mmol/L, p = 0.0006) and LDL-c concentrations (7.94 ± 1.86 mmol/L vs. 6.93 ± 1.78 mmol/L, p = 0.016), which were significantly higher in FH patients living in France, an observation that was revealed across all studied LDLR variants. Conclusions: This study illustrates that FH patients sharing IBD pathogenic LDLR variants that have evolved in different geographic, cultural, and socio-economic environments for hundreds of years differ in terms of cholesterol levels, highlighting the importance of better understanding the interplay between genetic and environmental modulators of FH expression.Keywords
All Related Versions
Funding Information
- ECOGENE-21 dedicated funds for the SMASH program
This publication has 19 references indexed in Scilit:
- Epigenetics and environmental healthFrontiers of Medicine, 2024
- Trends in epidemiology of dyslipidemias in IndiaIndian Heart Journal, 2024
- Genetic epidemiology of monogenic dyslipidemia and statin-associated adverse drug phenotypes in Indian population from whole-genomes of 1029 self-declared healthy individualsHuman Gene, 2023
- Special Patient Populations2023
- Differential DNA methylation in familial hypercholesterolemiaEBioMedicine, 2020
- Familial Hypercholesterolemia and the Founder Effect Among Franco-Americans: A Brief History and Call to ActionCJC Open, 2020
- Epigenetic programming, early life nutrition and the risk of metabolic diseaseAtherosclerosis, 2017
- The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum ofLDLRmutations and role ofPCSK9as a modifier geneHuman Mutation, 2009
- Molecular basis of familial hypercholesterolemia: An Indian experienceIndian Journal of Clinical Biochemistry, 2000
- Familial hypercholesterolemia in French-Canadians: Taking advantage of the presence of a “founder effect”The American Journal of Cardiology, 1993